Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-Blind, Randomized, Placebo-Controlled Study.

Trial Profile

Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-Blind, Randomized, Placebo-Controlled Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2015 Pooled analysis results of this trial and other two 24-Week , placebo-controlled trials presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 14 Aug 2013 Primary endpoint 'Severe-Impairment-Battery' has been met.
    • 14 Aug 2013 Results published in the Journal of Clinical Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top